Jeffreys now offers a compounded sublingual Semaglutide which can save you over 80% as compared to oral or injectable GLP-1 drugs on the market.

The usage of GLP-1 receptor agonists, such as semaglutide, has grown exponentially worldwide. This class includes both injectable and oral dosage forms. Many patients prefer to avoid injections if possible, however the oral absorption of GLP-1 receptor antagonists is extremely low. (less than 1% per the labeling for RYBELSUS® tablets). For these reasons, prescribers and their patients may prefer an alternative option such as compounded sublingual formulation of Semaglutide.

As this is a sublingual drug it is easy to administer as you will use 1 drop under your tongue once daily! No more weekly injections or oral drugs that are less effective after going through your digestive system.

If you believe that this unique product would benefit you, we would love to discuss how this formulation can help address patient needs where GLP-1 receptor agonists are useful.